Who owns BCRX?
Institutional ownership of BioCryst Pharmaceuticals Inc. from Form 13F, Q2 2026
318 institutional managers reported holding BioCryst Pharmaceuticals Inc. (BCRX) in Form 13F filings for Q2 2026, with 263,846,834 shares worth $2.6B. The largest reported holder was BlackRock, Inc. Managers that filed both quarters added a net 15,679,274 shares (+6.6%). 54 opened new positions and 37 sold out.
- Funds holding
- 318
- Value held
- $2.6B
- New / sold out
- 54 / 37
- Net shares, same filers
- +6.6%
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Largest holders of BCRX
| Fund | Value | Share of 13F holdings | Shares | Move |
|---|---|---|---|---|
| BlackRock, Inc. | $239M | 9.1% | 23,893,036 | Added |
| Ra Capital Management, L.p. | $158M | 6.0% | 15,827,186 | Unchanged |
| State Street Corp | $152M | 5.8% | 15,191,098 | Added |
| Deerfield Management Company, L.p. | $151M | 5.7% | 15,096,403 | Added |
| Vanguard Capital Management LLC | $114M | 4.3% | 11,364,236 | Added |
| Vanguard Portfolio Management LLC | $111M | 4.2% | 11,139,158 | Trimmed |
| TCG Crossover Management, LLC | $110M | 4.2% | 11,020,968 | Unchanged |
| Perceptive Advisors LLC | $103M | 3.9% | 10,308,888 | Added |
| Jupiter Topco LLC | $95.3M | 3.6% | 9,540,764 | First report |
| Vestal Point Capital, LP | $83.0M | 3.1% | 8,300,000 | Added |
| Two Sigma Investments, LP | $67.8M | 2.6% | 6,775,349 | Added |
| Geode Capital Management, LLC | $62.5M | 2.4% | 6,248,046 | Added |
| Aberdeen Group plc | $53.1M | 2.0% | 5,310,871 | Added |
| UBS Group AG | $50.8M | 1.9% | 5,078,280 | Added |
| Bank of America Corp | $48.0M | 1.8% | 4,801,284 | Trimmed |
| Goldman Sachs Group Inc | $44.8M | 1.7% | 4,481,874 | Added |
| Frazier Life Sciences Management, L.P. | $40.1M | 1.5% | 4,009,240 | Unchanged |
| Nuveen, LLC | $40.1M | 1.5% | 4,007,237 | Added |
| Nantahala Capital Management, LLC | $38.0M | 1.4% | 3,802,320 | Added |
| Millennium Management LLC | $33.9M | 1.3% | 3,394,729 | Added |
| GW&K Investment Management, LLC | $31.7M | 1.2% | 3,171,113 | Trimmed |
| Jane Street Group, LLC | $27.6M | 1.0% | 2,762,683 | Added |
| Dimensional Fund Advisors LP | $27.2M | 1.0% | 2,718,781 | Added |
| Fisher Asset Management, LLC | $26.0M | 1.0% | 2,604,027 | Trimmed |
| Renaissance Technologies LLC | $25.3M | 1.0% | 2,530,290 | Added |
Share of 13F holdings is each fund's shares as a share of the 263,846,834 BCRX shares all 13F filers reported, not of shares outstanding.
Biggest buyers in Q2 2026
- Millennium Management LLC Added+$32.1M
- State Street Corp Added+$29.8M
- Perceptive Advisors LLC Added+$28.7M
- Jane Street Group, LLC Added+$21.4M
- Goldman Sachs Group Inc Added+$21.3M
- Nantahala Capital Management, LLC Added+$18.1M
- AQR Capital Management LLC Added+$17.7M
- Renaissance Technologies LLC Added+$17.5M
- Vestal Point Capital, LP Added+$12.8M
- BlackRock, Inc. Added+$12.4M
Biggest sellers in Q2 2026
- Royalty Pharma Sub-Manager, LLC Sold out-$36.6M
- Kynam Capital Management, LP Trimmed-$31.6M
- RFG Advisory, LLC Sold out-$27.3M
- Susquehanna International Group, LLP Trimmed-$16.2M
- Eversept Partners, LP Trimmed-$11.7M
- JPMorgan Chase & Co Trimmed-$9.9M
- Jacobs Levy Equity Management, Inc Sold out-$9.6M
- Schonfeld Strategic Advisors LLC Trimmed-$6.3M
- Hillsdale Investment Management Inc. Sold out-$6.1M
- Man Group plc Trimmed-$5.6M
The change in shares since the quarter before, adjusted for stock splits and priced at the Q2 2026 value per share. Funds bought $386M and sold $224M; 131 added and 84 trimmed.
Schedule 13D and 13G filings on BCRX
Owners of more than 5% must file within days, so these can be newer than the 13F data.
- 2026-11-10STATE STREET CORP SCHEDULE 13G filed by BioCryst Pharmaceuticals Inc.Schedule 13G
- 2026-08-07STATE STREET CORP SCHEDULE 13G filed by BioCryst Pharmaceuticals Inc.Schedule 13G
- 2026-05-12STATE STREET CORP SCHEDULE 13G filed by BioCryst Pharmaceuticals Inc.Schedule 13G
- 2026-02-09STATE STREET CORP SCHEDULE 13G filed by BioCryst Pharmaceuticals Inc.Schedule 13G
Questions about BCRX ownership
- Who owns BCRX stock?
- 318 institutional investment managers reported BCRX positions in their Form 13F filings for Q2 2026, holding 263,846,834 shares worth $2.6B in total. BlackRock, Inc. reported the largest position.
- Are funds buying or selling BCRX?
- In Q2 2026, 54 managers opened new BCRX positions, 131 added, 84 trimmed and 37 sold out. Managers that filed in both quarters added a net 15,679,274 shares.
- How current is this BCRX institutional ownership data?
- It covers holdings as of the end of Q2 2026. Managers have 45 days after the quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
From the SEC's Form 13F data sets for Q2 2026: every 13F holdings report, matched to BCRX by CUSIP. Options are left out. BCRX news and filings · BCRX insider trades · Top funds